Company
Damona
Our lead program is a best-in-class positive allosteric modulator (PAM) that targets the α5-GABA-A receptor.
Also known as Damona Pharmaceuticals Inc
- Status
- Operatingas of 2026-09-17
- Legal name
- Damona Pharmaceuticals Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Damona is focused on discovering and developing precision neuromedicines for patients living with cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer’s disease, depression, and schizophrenia.
Funding snapshot
- Total raised
- $5.5MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Seed, $5.5M2022-09-22
Funding rounds
- Seed
- $5.5M2022-09-22, Company stated
Products
- Other
- DPX-101
Loading relationship preview